在 duvakitug 显示出治疗炎症性肠病的前景后，Teva 和 Sanofi 的股票飙升。 Ticker stocks for Teva and Sanofi soar after duvakitug shows promise in treating inflammatory bowel diseases.

在治疗溃疡性结肠炎和克罗恩病的药物 duvakitug 的 2b 期试验结果成功后，Teva 和 Sanofi 的股票股票飙升。 Ticker stocks for Teva and Sanofi surged after successful Phase 2b trial results for duvakitug, a drug treating ulcerative colitis and Crohn's disease. 与安慰剂相比,该药物显著改善了缓解和反应率,没有发现安全问题. The drug showed significant improvements in remission and response rates compared to placebo, with no safety concerns identified. Teva的库存增长了20%以上,反映了该药物作为流行性肠道疾病的主要治疗方法所具有的潜力。 Teva's stock rose over 20%, reflecting the drug's potential as a leading treatment for inflammatory bowel diseases.